COMING SEPTEMBER 18TH, 2021

Saturday, September 18, 2021

  • ADHD and Substance Use Disorder Saturday, September 18, 2021 | 11:00:AM - 12:00:PM CT

    Add to Calendar 09/18/2021 11:00 AM 09/18/2021 12:00 PM America/Chicago ADHD and Substance Use Disorder Sponsored by Attention-deficit/hyperactivity disorder (ADHD) is a diagnosis that is typically first seen in childhood and adolescence, and symptoms will often continue through adulthood.  For some, the diagnosis is not made until adulthood, for a variety of reasons.  ADHD can affect all areas of one’s life, including school, work, family and social relationships.  The impact of untreated or undertreated ADHD can be seen with an individual’s success (or failure) in education and occupation, in one’s family relationships, in society in general and in the health care system.  Unfortunately, ADHD is not usually seen in isolation, particularly in the adult population.  One of the more common comorbid conditions of ADHD is Substance Use Disorder (SUD).   Comorbid ADHD-SUD is associated with worse outcomes than SUD alone. Patients with concurrent ADHD-SUD experience a more severe course of SUD, characterized by earlier onset of substance abuse, lower remission rates, more substance dependence and psychiatric diagnoses.    In comorbid cases, ADHD usually precedes the onset of anxiety and substance use disorders, suggesting that ADHD may be, directly or indirectly, a causal factor in the etiology of SUD during adulthood.  ADHD also elevates the risk of transition from drug abuse to drug dependence and from alcohol to drug use. The prevalence, burden, and severity of comorbid ADHD-SUD are significant and highlight the importance of effectively managing the condition. Controversy remains regarding the pharmacological treatment of ADHD when comorbid SUD is present, and a multimodal approach is recommended.  Treatment goals include stabilizing ADHD symptoms, reducing substance use and promoting abstinence.  Recent studies have shown that pharmacotherapy may be effective in treating ADHD patients with comorbid SUD, helping them overcome their addiction. Dr. Larry J. Klassen, MD Dr. Larry Klassen is a psychiatrist at Eden Mental Health Centre in Manitoba, Canada, who specializes in the treatment of adults with Mood and Anxiety Disorders, as well as ADHD.  He is involved in the ongoing education of residents and medical students at the University of Manitoba, providing educational opportunities within his varied clinical practice. In 2008 Dr. Klassen was named Research Chair of the Eden Mental Health Centre, and has developed a research program that is focused on Mood and Anxiety disorders, as well as ADHD in adults.  He is the lead author on a number of research publications looking at ADHD as well as comorbidities.  He has co-authored and worked on numerous other publications and projects focused on ADHD, Mood and Anxiety disorders, including the Canadian Anxiety Disorders guidelines.  Dr. Klassen has a clinical practice in general outpatient psychiatry.   This involves expert consultation, diagnosis, treatment and follow-up.   https://eventsvirtually.org/adhd-and-substance-use-disorder-sponsored-by-takeda
  • Pharmacists Manitoba Awards Presentation Saturday, September 18, 2021 | 12:00:PM - 12:30:PM CT

    Add to Calendar 09/18/2021 12:00 PM 09/18/2021 12:30 PM America/Chicago Pharmacists Manitoba Awards Presentation https://eventsvirtually.org/pharmacists-manitoba-awards-presentation
  • Resource Centre Saturday, September 18, 2021 | 12:30:PM - 01:15:PM CT

  • Reducing Stigma and Increasing Resilience: The Working Mind Saturday, September 18, 2021 | 01:15:PM - 02:15:PM CT

    Add to Calendar 09/18/2021 01:15 PM 09/18/2021 02:15 PM America/Chicago Reducing Stigma and Increasing Resilience: The Working Mind This program is not accredited; for more information on the full accredited program go to www.theworkingmind.ca Sponsored by Opening Minds, a division within the Mental Health Commission of Canada (MHCC), is the largest systematic effort in Canadian history focused on reducing stigma related to mental illness. Established by MHCC in 2009, it seeks to change Canadians’ attitudes and behaviours toward people living with mental illness to ensure they are treated fairly and as full citizens with opportunities to contribute to society like anyone else. Over 700,000 people have been trained in either Mental Health First Aid or The Working Mind, world-class evidence-based mental health training programs put forward by Opening Minds. In this presentation you will learn about: (1) Foundational concepts like the mental health continuum and the big 4 coping strategies and how they reduce stigma and increase resilience in a workplace environment  (2) Evolution and impact of The Working Mind mental health training program designed for employees and leaders (3) Specific adaptations for Healthcare providers and First Responders (4) Stories of recovery through contact-based education You will leave this presentation feeling inspired with tangible tools to take forward to begin changing the culture on mental health within your workforce. Resource Links: Resource Hub: Mental health and wellness during the COVID-19 pandemic COVID-19 Resources: Healthcare Providers Healthcare Providers Micheal Pietrus, Director, Opening Minds & MHFA Canada Micheal Pietrus is the Director of the Mental Health Commission of Canada’s international award-winning anti-stigma initiative Opening Minds. In February 2015, Opening Minds received the Innovator Award from the organizers of the 7th Together Against Stigma Conference in San Francisco. He is also the Director of Mental Health First Aid Canada. Under Micheal’s leadership, the Commission launched Opening Minds, its anti-stigma/anti-discrimination initiative in 2009, which is the largest systematic effort to reduce the stigma of mental illness in Canadian history. He was appointed Director of Mental Health First Aid (MHFA) Canada in July 2015. Micheal and his team of researchers worked with public safety organizations across Canada to develop The Working Mind Program for First Responders (formerly known as R2MR). This evidence-based program has been shown to be effective at reducing stigma, increasing resiliency and improving mental wellness. To date more than 100-thousand police, fire and EMS personnel across the country have taken the training. He has presented on his team’s research and TWM for First Responders at conferences in Canada, U.S., Europe and Australia. Working with researchers and police trainers, his team has developed a new MHFA program specifically designed for law enforcement officers. The OPP are the first police service to operationalize the program. He is a co-founder of the Global Anti-stigma Alliance, which is composed of more than 20 international organizations working to reduce the stigma associated with mental illness. Micheal is also a founding member of a South American anti-stigma consortium. It is membership includes researchers from medical schools in Chile, Peru, Brazil, Argentina and Bolivia. He is a former member of the Board of the Alberta Lieutenant Governor’s Circle on Mental Health and Addictions. Micheal was also a Director with the Alberta Mental Health Board.   https://eventsvirtually.org/reducing-stigma-and-increasing-resilience-the-working-mind-sponsored-by-pharmasave
  • Protect Your Patients!
    The pharmacist’s role in preventing Pneumococcal Disease, Seasonal Influenza and COVID-19
    Saturday, September 18, 2021 | 02:45:PM - 03:45:PM CT

    Add to Calendar 09/18/2021 02:45 PM 09/18/2021 03:45 PM America/Chicago Protect Your Patients!
    The pharmacist’s role in preventing Pneumococcal Disease, Seasonal Influenza and COVID-19
    Sponsored by &        Over the last year and a half, COVID-19 has fundamentally changed our way of life and stretched our hospital capacity beyond its limit. How can pharmacists contribute to public health and ensure their patients are best protected against pneumococcal disease, seasonal influenza, and COVID-19? Josée-Anne Le Dorze, BScPharm Josée-Anne is the co-founder of Simplicity Wellness, a health coaching and chronic disease management practice. With 10 years of experience in community practice, Josée-Anne obtained her Certificate in Travel Health from the International Society of Medicine in 2019. She strongly supports an expanded scope of practice for community pharmacists in Manitoba, and believes we must play a critical role in ensuring Manitobans are vaccinated according to best practice.   https://eventsvirtually.org/protect-your-patients-the-pharmacists-role-in-preventing-pneumococcal-disease-seasonal-influenza-and-covid-19-sponsored-by-pfizer-sanofi

On Demand

  • Adverse Reaction Reporting: Your Role in Patient Safety   Adverse Reaction Reporting: Your Role in Patient Safety  This session will define the role of health professionals and Health Canada in the process of reporting suspected adverse drug reactions (ADRs) to health products to help minimize risks, including how to report and what type ...

  • CADTH Top 10 What does the evidence say about current pharmacy topics?  This presentation will review the key findings from ten recent CADTH evidence reviews. This is your ‘ top ten playlist’ to stay up to date on the questions decision makers and clinicians are asking about drugs and ...

  • Evolving Guidelines in Multiple Sclerosis Treatment Sponsored by Roche Dr. Ciftci will be discussing the evolving guidelines in multiple sclerosis treatment, and the challenges encountered in the clinical setting. Dr. Beyza Ciftci, M.D. Beyza Ciftci recently joined the Health Sciences Centre, University of Manitoba (Winnipeg, MB) as an Assistant Professor ...

  • College of Pharmacy – Dean’s Update Sponsored by Rady Faculty of Health Sciences   Dean’s Update - Dean Lalitha Raman-Wilms Year 3 PharmD – Dr. Lavern Vercaigne IPPE/APPE (Introductory/Advanced Pharmacy Practice Experience) – Mr. Ron Eros Research Project Course – Dr. Silvia Alessi-Severini Indigenization of the Pharmacy Curriculum - Ms. Nancy Kleiman

  • Beyond Stressed Stress can affect many are of our physiological pathway in our body and understanding the effects and how to support and modulate it will have far better result for our patients. This presentation will discuss how stress effect these different physiological pathways and nutrients and ...

  • Digital Health and Pharmacy – Is the Future Here? A year ago, virtual care, wearables and digital therapeutics were all concepts that seemed to be impossible to reconcile with the traditional role of pharmacists. With COVID-19, we have seen a rapid adoption of these innovations in the health care field. What opportunities do they ...

  • Management Considerations for Idiopathic Pulmonary Fibrosis (and other Interstitial Lung Diseases) Pending Program Dr. Colbourne will provide a brief overview of the diagnostic evaluation, clinical history and prognosis of IPF followed by a review of the evidence, adverse effects, and monitoring parameters of antifibrotic therapy in the treatment of IPF and other fibrosing ILDs.  A discussion around other ...

  • Saving Lives in the "Other" Crisis - Implementing the Canadian National Consensus Guidelines for Naloxone Prescribing by Pharmacists Sponsored by While the COVID-19 pandemic has fundamentally altered the way we live and killed more than 25,000 Canadians, a second deadly crisis also continues to rage. A record number of Canadians died of opioid toxicity in 2020, including at least 254 Manitobans. Pharmacists play a key public ...

  • Smoking Cessation Programs across Canada Sponsored by MLT AIKINS Pharmacist Smoking Cessation Programs across Canada will be examined. Discover how each province provides different reimbursement models for smoking cessation medications, pharmacist individual counselling and pharmacist group counselling. Understand how university curriculums for pharmacy students as well as continuing education programs ...

  • Starting the Conversation: The Role of Sensor-Based Technology in Diabetes Management Sponsored by Abbott By the end of this session, delegates will be able to: 1) Explain the role of sensor-based technology in the management of diabetes 2)Differentiate the value of utilizing sensor-based glucose information versus finger stick glucose 3) Facilitate discussions for enhancing patient’s ability to ...

  • Treatment Considerations and Strategies for Optimizing COPD Management Sponsored by Using the latest guidelines and data, this session will address treatment considerations and strategies for COPD patients. Hot topics such as intensifying early treatment, safety, inhaler devices and Asthma COPD Overlap (ACO) will be discussed.   Dr. Lawrence Homik, MD, FRCPC Lawrence Homik is ...